In this study, doctors from Italy investigated the usefulness of newly proposed hepatocellular carcinoma (HCC) prognostic systems in anti-HCV positive cirrhotic patients with HCC:
- The Cancer of the Liver Italian Program (CLIP) score
- The Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH) model
- The Barcelona Clinic Liver Cancer (BCLC) staging classification
The team compared these with the known Okuda staging system.
|All staging systems were able to identify the various patient subgroups.|
|Journal of Internal Medicine|
The doctors retrospectively applied the Okuda stage, CLIP score, GRETCH model and BCLC stages in 81 anti-HCV positive cirrhotic patients with HCC.
They compared the ability of these methods to assess survival prognosis.
Overall, 51 patients died and median survival was 18 months.
The team found that all staging systems were able to identify the various patient subgroups with differing survival.
They determined that the CLIP score, the GRETCH model and the BCLC staging classification were better at characterizing 1-year prognosis, compared to the Okuda staging system.
Dr Giannini's team concluded, "The prognostic value and usefulness of the CLIP score, the GRETCH model and the BCLC staging classification was reproduced in a single-centre analysis of anti-HCV positive HCC cirrhotic patients".
"These scores provided a prognostic assessment of our patients which is superior to what was obtained by the Okuda staging system".